Can I Take Glycine with Egrifta (Tesamorelin)?
Key numbers
- 1.4 mgEgrifta SV (tesamorelin) dose, injected under the skin into the abdomen once dailySource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 5%Tesamorelin-treated patients reaching HbA1c 6.5% or higher by week 26, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 3 gGlycine dose taken at bedtime for 3 nights in a sleep study (a study dose, not a recommendation)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
At a glance
- Drug / Egrifta SV (tesamorelin) 1.4 mg subcutaneously once daily [1]
- Supplement / Glycine, a non-essential amino acid sold over the counter as a dietary supplement
- Direct interaction data / No human study of the pair found
- Glycine in the Egrifta SV label / Not named; that section covers CYP450-metabolized drugs and glucocorticoids [1]
- Unestablished / Whether glycine adds to tesamorelin's growth hormone or IGF-1 effects
- What the label asks prescribers to monitor / IGF-1 and glucose during tesamorelin therapy [1]
- Glycine doses in human studies / 3 g at bedtime for 3 nights [3]; about 5 g per dose, three times daily, per the abstract's wording, for 3 months in type 2 diabetes [4]
Does glycine interact with tesamorelin?
No human interaction study of this pair was found. What the Egrifta SV label covers in its drug interactions section is narrower. For drugs metabolized by CYP450 enzymes, the label notes that growth hormone may alter clearance and asks prescribers to monitor for interactions; in healthy subjects tesamorelin changed simvastatin exposure by about -8% (AUC) and ritonavir exposure by about -9% (AUC), which the label describes as no significant impact [1]. For glucocorticoids, growth hormone inhibits 11-beta-HSD1, the enzyme that converts cortisone and prednisone into active cortisol or prednisolone, and the label says people on replacement therapy for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin [1]. Glycine appears nowhere in that section [1].
Tesamorelin itself is a 44-amino-acid peptide injected subcutaneously, with a median time to peak plasma level of 0.15 hours and an elimination half-life of about 8 minutes after a 1.4 mg dose in healthy subjects; the label states that no formal human metabolism studies have been performed [1]. The label gives the Egrifta SV dose as 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, with injection sites rotated [1].
Questions worth asking
Does glycine raise growth hormone?
One study measured this directly. Kasai and colleagues gave 19 nonobese normal subjects 250 mL of a 0.3 M glycine solution by mouth and found a clear, significant rise in serum human growth hormone (P<0.001); insulin, prolactin and blood sugar were unchanged [2]. The rise was larger in 12 people with partial gastrectomy, and giving glycine into the duodenum produced a similar rise in the normal subjects [2]. In nonobese people with diabetes, no significant growth hormone rise was seen even after intraduodenal glycine [2].
That was a single oral dose of 250 mL of 0.3 M glycine solution (roughly 5.6 g of glycine, by calculation), not a nightly regimen, and growth hormone was not measured after repeated dosing. The glycine sleep trial used 3 g before bed and reported next-day fatigue, sleepiness, psychomotor vigilance and plasma melatonin as its measures; it did not test glycine with tesamorelin or measure growth hormone [3]. Across three nights of sleep restricted to about 25% below usual, 3 g of glycine at bedtime significantly reduced fatigue on a visual analog scale, showed a tendency toward reduced sleepiness, and improved psychomotor vigilance, while melatonin was unchanged [3].
What tesamorelin does to IGF-1 and glucose
Tesamorelin binds and stimulates human GRF receptors on pituitary somatotroph cells, so the pituitary synthesizes and releases more of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [1]. Among patients treated for 26 weeks in the trials, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [1]. The label asks prescribers to monitor IGF-1 during therapy and to consider discontinuing if levels stay high (for example above 3 SDS), particularly when the fat-loss response is not robust, and states that the effects of prolonged IGF-1 elevation are unknown [1].
On glucose, an HbA1c of 6.5% or higher developed in 5% of tesamorelin-treated patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1]. The label asks prescribers to evaluate glucose before starting and to monitor periodically during treatment, and to monitor people with diabetes for development or worsening of retinopathy [1]. The phase 3 trials excluded people with type 1 or type 2 diabetes and anyone previously treated with insulin, oral glucose-lowering drugs or insulin-sensitizing agents, so those figures come from patients without diabetes at baseline [1].
Does glycine change blood sugar?
One randomized trial tested this in people with diabetes. Seventy-four adults with type 2 diabetes took glycine or placebo for 3 months (the abstract lists 5 g/d, taken orally three times daily), and HbA1c was significantly lower in the glycine group at the end of treatment [4]. In the 1978 growth hormone study, blood sugar was unchanged after oral glycine in nonobese normal subjects [2]. Neither study involved tesamorelin.
Glycine doses in human studies
These are study doses, not recommended doses. The sleep study used 3 g before bedtime for 3 nights [3]. The diabetes trial used the 5 g regimen described above for 3 months [4]. A separate trial of combined glycine and N-acetylcysteine (1:1) used 2.4, 4.8 or 7.2 g/day for 2 weeks in 114 healthy older adults [7]. Schizophrenia trials of glycine added to clozapine used 30 to 60 g/day, 10 to 20 times the 3 g sleep dose [5][6].
The combined glycine and N-acetylcysteine supplement was described as safe and well tolerated in the 24-person, 16-week trial and in the 114-person, 2-week dose trial; neither report gives a separate side-effect list for glycine alone [8][7].
What the Egrifta SV label says to watch for
Across the trials, 740 HIV-infected patients received tesamorelin, and 543 took it during the 26-week placebo-controlled phase [1]. The label reports injection-site reactions in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks [1]. In its table of adverse reactions, joint pain was 13% versus 11% on placebo, peripheral edema 6% versus 2%, and muscle pain 6% versus 2% [1].
Hypersensitivity reactions occurred in 4% of treated patients and included itching, redness, flushing, hives and rash; in suspected cases the label advises patients to seek prompt medical attention and to stop treatment [1]. Fluid retention, including edema, joint pain and carpal tunnel syndrome, is a labeled warning [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Can I take glycine with Egrifta (tesamorelin)?
Does glycine raise growth hormone?
Will glycine push my IGF-1 higher while I am on tesamorelin?
Does glycine affect blood sugar?
What glycine dose did the studies use?
Are there side effects from glycine?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How to use egrifta?
Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected under the skin of the abdomen once daily, with injection sites rotated.
How fast does egrifta work?
The timing of fat-loss effects is not stated. The only timing given is for blood levels: after a 1.4 mg dose in healthy subjects, the median time to peak plasma level was 0.15 hours, and the elimination half-life was about 8 minutes.
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Kasai K, Kobayashi M, Shimoda SI. Stimulatory effect of glycine on human growth hormone secretion. Metabolism. 1978;27(2):201-8.
- Bannai M, Kawai N, Ono K, Nakahara K, Murakami N. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Front Neurol. 2012;3:61.
- Cruz M, Maldonado-Bernal C, Mondragón-Gonzalez R, Sanchez-Barrera R, Wacher NH, Carvajal-Sandoval G, et al. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J Endocrinol Invest. 2008;31(8):694-9.
- Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 1999;156(1):145-7.
- Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000;157(5):826-8.
- Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, et al. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Front Aging. 2022;3:852569.
- Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89.